Analysis of the application status and prescription trends of 5 neuroprotective agents in acute ischemic stroke
Objective To analyze the current application status and prescription trends of 5 neuroprotective agents for im-proving nerve function in patients with acute ischemic stroke(AIS)in China.Methods Prescriptions with the diagnosis of AIS from 2016 to 2022 were extracted from the Hospital Prescription Analysis Cooperation Project(HPACP)database for retrospec-tive analysis.Patient characteristics,including gender,age,city type,prescription time,department of visit,original diagno-sis,drug name,dosage,drug daily cost,payment method,etc.,were collected to analyze the current usage status and pre-scription trends of 5 neuroprotective agents and discuss their rational use.Results A total of 1 064 264 prescriptions were in-cluded in the analysis,and the number of prescriptions for edaravone,edaravone dexborneol,urinary kallidinogenase,bu-tylphthalide,and cinepazide maleate were 575 490,42 826,75 023,285 230,and 85 695,respectively.Most of the pa-tients were male(63.08%),and the median age was 66 years old.Prescriptions from tertiary hospitals accounted for 95.59%,and 86.81%of patients were from inpatient wards.The daily drug cost for edaravone dexborneol was the highest(292.80 yuan)and the lowest was 100.00 yuan for urinary kallidinogenase.The number of edaravone and cinepazide male-ate prescriptions decreased yearly,while the numbers of butylphthalide,urinary kallidinogenase,and edaravone dexborneol,prescriptions increased yearly.Prescriptions for combined use of neuroprotective agents totaled 118 676(11.15%),with 5819(0.55%)involving three or four agents used in combination.Conclusion The use of neuroprotective agents in AIS is decreas-ing annually.Butylphthalide,urinary kallidinogenase,and edaravone dexborneol are currently the most commonly used neu-roprotective agents.There are also irrational cases of combined use of multiple neuroprotective agents,which should be given more attention.
NETL
NSTL
万方数据
